
|Articles|May 19, 2015
- Genitourinary (Issue 2)
- Issue 2
AR-V7 as a Biomarker in CRPC
Author(s)Emmanuel S. Antonarakis, MBBCh
Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine, discusses the potential of AR-V7 as a biomarker in early stage castration-resistant prostate cancer (CRPC).
Advertisement
Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine, discusses the potential of AR-V7 as a biomarker in early stage castration-resistant prostate cancer (CRPC).
<<<
Articles in this issue
over 10 years ago
Use of ARN-509 in Prostate Cancerover 10 years ago
Abiraterone Plus Low-Dose Prednisone Lowers PSA in High-Risk M0 CRPCover 10 years ago
Study Illuminates Role of AR-V7 in Carcinogenesisover 10 years ago
PSA Screening Drops 50% Following USPSTF Recommendationover 10 years ago
Urine-Based Diagnostic Effectively Identifies Prostate Cancerover 10 years ago
Trends in PSA Utilization in Primary Care PhysiciansAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5








































